GİRİŞ VE AMAÇ

12. Tanagho E. A., McAninch J.W. Smith’s general urology. 4.ed. San Francisco: A.
Simon & Schuster Company, 1995: 410-27.
13. Drago J.R., Goldman L. B.,Gershwin M.E. Evaluation of nonhormonal cytotxic
chemotherapy in the nb rat prostate adenocarcinoma. Cancer 1980; 46: 273-8.
14. Walsh P.C. Campbell’s urology. Vol.4. Philadelphia: Saunders, 2002: 3003-82.
15. Çal Ç, Cüreklibatır İ. Prostat kanserinde tedavi. 1. Baskı. İzmir: Deomed Medikal
Yayıncılık, 2003: 1-210.
16. Grossfeld G. D., Hayward S. W., Tısty T. D., Cunha G.R. The role of stroma in
prostatic carcinogenesis. Endocrine-Related Cancer 1998; 5: 253-70.
17. Korkud G., Karabay K. Üroloji. İstanbul: İstanbul Üniversitesi Basımevi, 1993:584 -
92.
18. Kumar V., Cotran R. S.,Robbins S. L. Basc payhology. 6.Ed. İstanbul: Nobel, 2000:
586-8.
19. Bowsher W. Challenges in prostate cancer. 1.Pub. London: Blackwell Science Ltd
Editorial Offices, 2000:19-49.
20. Epstein J.I. Diagnostic criteria of limited adenocarcinoma of the prostate on needle
biopsy. Human Pathology 1995; 26 (2): 223-9.
21. Eble J. N., Sauter G., Epstein J.I., Sesterhenn Pathology and genetics of tumours of the
urynary system and male genital organs. Lyon: World Health Organization
Classification of Tumours, 2004: 159-214.
22. İnci O. Ürogenital tümörler. İstanbul: Nobel Tıp Kitabevleri, 1995: 106-34.
23. Leong F. J. W. M., Leong A.S.Y. and Swift. J. Signet-ring carcinoma of the prostate.
Path Res Pract 1996; 192 (12): 1232-8.
24. Fink D.J., Galen R. S. Immunologic dedection of prostatic acid phosphatase. Human
Pathology 1978; 9 (6): 621-3.
25. Wojno K. J., Epstein J. I.. The utility of basal cell-specific anti-cytokeratin antibody
(34Βe12) in the diagnosis of prostate cancer. Am J Surg Pathol 1995;19 (3): 251-60.
26. Tolunay Ö. Prostat kanseri tanısında immünohistokimya.Ege Patoloji Derneği,
XIV.Ulusal Patoloji Kongresi; 1999 Nisan 11-17; Antalya, Türkiye. İzmir; 1999.
27. Umbas R., Isaacs W. B, Bringuier P. P., Schaafsma H. E., Karthaus H. F. M.,
Oosterhof G.O.N. et al. Decreased e-cadherin expression is associated with poor
prognosis in patients with prostate cancer. Cancer Research. 1994; 54: 3929-33.
55